Grace Therapeutics, Inc. (GRCE) Investor Relations Documents

Grace Therapeutics, Inc. (GRCE) investor relations documents from the company's IR site: 1 presentation, 26 press releases; latest deck 2026-04-26. Read in-app with summaries. First-party data.

View Presentation: Grace Therapeutics is addressing a Complete Response Letter for its IV nimodipine candidate, GTx-104, intended to treat aneurysmal subarachnoid hemorrhage.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-13Press releaseGrace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
2026-08-04Press releaseGrace Therapeutics Announces $10 Million Private Placement
2026-07-28Press releaseGrace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration
2026-06-18Press releaseGrace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update
2026-06-18Press releaseEarnings Release FY 2026 PDF
2026-04-26PresentationView Presentation
2026-04-23Press releaseGrace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
2026-04-14Press releaseGrace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026
2026-03-19Press releaseGrace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH
2026-02-25Press releaseGrace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
2026-02-12Press releaseGrace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update
2026-02-12Press releasePDF
2025-11-13Press releasePDF
2025-08-27Press releaseGrace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104
2025-08-12Press releaseGrace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update
2025-08-12Press releasePDF
2025-08-12Press releaseEarnings Release Q1 2026 PDF
2025-06-25Press releaseGrace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
2025-06-23Press releasePDF
2025-06-23Press releaseEarnings Release FY 2025 PDF
2025-02-25Press releaseGrace Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
2025-02-13Press releasePDF
2025-02-13Press releaseEarnings Release Q3 2025 PDF
2024-12-04Press releaseGrace Therapeutics to Exhibit at the American Society of Health-System Pharmacists Conference
2024-11-13Press releasePDF
2024-11-13Press releaseEarnings Release Q2 2025 PDF
2022-02-14Press releasePDF

GRCE overview · GRCE earnings · GRCE financials · GRCE KPIs · GRCE ownership · GRCE peers · GRCE filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.